A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver
Status:
Active, not recruiting
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
This study is intended to determine the safety, tolerability and reduction of biochemical
markers (Chromogranin A or, if deemed appropriate, 5-hydroxyindoleaceticacid) and troublesome
symptoms (particularly diarrhea and flushing) of intralesional injection of PV-10 in subjects
with NET metastatic to the liver that are not amenable to resection or other potentially
curative therapy.